Invitrogen has announced a number of appointments under its corporate realignment, which is to take effect on Jan. 1 (see feature in this issue). John "Kip" Miller has joined the company as senior vice president of the Enabling Technologies division. He joins the company from BD Biosciences, where he served as vice president and general manager, Americas.
Jon Hindar has been named senior vice president of the new Life Sciences division. He was CEO of Dynal, until that firm was acquired by Invitrogen earlier this year. Nicolas Barthelemy, Invitrogen's head of global operations, will lead the Bio-Production Systems and Services division.
Daryl Faulkner, senior vice president of global business segments, will retire during the first quarter of 2006 after seven years with the company.
In addition, a few of Invitrogen's top executives are getting raises effective Jan. 1, 2006, according to an 8-K filing with the US Securities and Exchange Commission this week.
The compensation and organizational development committee of Invitrogen's board of directors approved a raise in CFO David Hoffmeister's base annual salary to $440,000. Claude Benchimol, senior vice president of R&D, will receive a base salary of $405,000, and Ben Bulkley, senior vice president of commercial operations, will receive a base salary of $385,000.
Gregory Schiffman has been added to Nanomix's board of directors, the nanotechnology company said this week. He has also been appointed chairperson of Nanomix's audit committee.
Schiffman is currently the executive vice president and chief financial officer of Affymetrix. He joined Affymetrix in 2001 from Applied Biosystems where he held the position of vice president, controller. He also has experience in finance, manufacturing and distribution management from his prior tenure with Hewlett Packard and IBM.
Schiffman holds a BSc from DePaul University and an MBA from Northwestern University.
Sequenom has hired three genetic analysis specialists for its Genetic Services unit, the company said last week.
Jeffrey Otto has been named director of genetic services, Min Seob Lee as manager of genetic services, and Donald Benson as genetic services national account manager. Sequenom launched its new genetics analysis service business in October.
Otto most recently worked for Genaissance Pharmaceuticals and holds an MBA from Ellis College of the New York Institute of Technology. He also holds a PhD from Marquette University. Lee holds an MS in biology from California State University, Los Angeles, and a BSc in biology from Kyung-Hee University in Seoul, Korea.
Benson worked previously for Boehringer Mannheim Biochemicals, Eppendorf North America, Genaissance, Orchid Biosciences, Qiagen and other firms, Sequenom said. He holds a BSc from Rutgers University.
Guava Technologies said last week that it has promoted Lawrence Bruder to the position of CEO. Bruder served as Guava's chief operating officer and president since July, when he was promoted to the position. Prior to that, he served as vice president of corporate development and worldwide marketing. He has held vice-president-level positions at Applied Biosystems and Becton Dickinson, and has held various marketing, sales, and product management positions with Leica and Olympus. He holds a master of management degree from Kellogg Management School at Northwestern University, and a BS from Rochester Institute of Technology.
Guava also hired Todd Christian as vice president, commercial operations, and Lalit Dhir as vice president of corporate development and strategic marketing. Christian previously was served various roles in product development, program management, and global marketing across multiple business units at Applied Biosystems, and served as general manager of ABI's cell biology incubator. Prior to this, he was a general manager for BD Biosciences' Canadian operations. He also has served as director or program management, product development, custom products, and marketing with BD Biosciences. He holds a BA in biology from Hamilton College.
Dhir joined Guava from BD Biosciences, where he led strategy planning and corporate development. He also served as manager of business development at BD's Pharmingen division. He holds an MBA from San Diego State University, and an MS and BS in biochemistry from Panjab University in India.